Carcinogenicity of Perfluorooctanoic Acid and Perfluorooctanesulfonic Acid

Details

• Personal Author:
  Abdallah M ; Ahmadi A ; Ahmadi N ; Benbrahim-Tallaa L ; Bijoux W ; Blystone CR ; Bonde JP ; Calkins MM ; Chittiboyina S ; Chiu WA ; de Conti A ; Dong GH ; Dorman DC ; Facchin C ; Fletcher T ; Fry R ; Guo H ; Haug LS ; Hofmann JN ; Hoppin J ; Iwasaki M ; Kanno J ; Machala M ; Madia F ; Mancini FR ; Maria-Engler SS ; Mattock H ; Merdas M ; Møller P ; Ng JC ; Pallardy M ; Pasqual E ; Post GB ; Salihovic S ; Schlezinger J ; Schubauer-Berigan, Mary K. ; Soshilov A ; Steenland, Kyle ; Steffensen I-L ; Suonio E ; Tryndyak V ; Viegas S ; Wedekind R ; White A ; Woskie S ; Zahm S ; Zupunski L
• Description:
  In November, 2023, a Working Group of 30 scientists from 11 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of two agents: perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), including their corresponding isomers and salts. PFOA was classified as "carcinogenic to humans" (Group 1) based on "sufficient" evidence for cancer in experimental animals and "strong" mechanistic evidence in exposed humans. The evidence for cancer in experimental animals was "sufficient" because an increased incidence of an appropriate combination of benign and malignant neoplasms was observed in both sexes of a single species in a Good Laboratory Practice (GLP) study. The mechanistic evidence was "strong" in exposed humans because PFOA was found to induce epigenetic alterations and to be immunosuppressive. Additionally, there was "limited" evidence for cancer in humans for renal cell carcinoma and testicular cancer. PFOS was classified as "possibly carcinogenic to humans" (Group 2B) based on "strong" mechanistic evidence. The evidence for cancer in experimental animals was "limited" for PFOS, and the evidence regarding cancer in humans was "inadequate". These assessments will be published in Volume 135 of the IARC Monographs. [Description provided by NIOSH]
• Subjects:
  Carcinogens Neoplasms Occupational Exposure Occupational Health Safety
• Keywords:
  Cancer Carcinogen Policy Chemicals Occupational Exposure Recommendations
• ISSN:
  1470-2045
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  Ohio ; OSHA Region 5
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  DSI - Division of Science Integration
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  16-17
• Volume:
  25
• Issue:
  1
• NIOSHTIC Number:
  nn:20069133
• Citation:
  Lancet Oncol 2024 Jan; 25(1):16-17
• CAS Registry Number:
  Perfluorooctanesulfonic acid (CAS RN 1763-23-1) ; Perfluorooctanoic acid (CAS RN 335-67-1)
• Federal Fiscal Year:
  2024
• Peer Reviewed:
  True
• Source Full Name:
  The Lancet Oncology
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:5fe0038b2be2300ccaec647d35dd5ad37eef339be1a8c01303c50a7cf8128af994df50c2de7257229f30417e6b63b5f056c4be32a8493878b97f44529bad864b
• Download URL:
  https://stacks.cdc.gov/view/cdc/207670/cdc_207670_DS1.pdf
• File Type:
  [PDF - 101.94 KB ]